Combined Holdings of Intellia Therapeutics (NTLA) - Updated Daily
Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 2.51% | $3.26b |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 14 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$54.51 - ARKG$62.04 - ARKK | 9.71% |
| Description | |
|---|---|
| Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. | |
| Website | |
| www.intelliatx.com |
Other ETFs That Hold NTLA
Research Notes and Commentary for NTLA
October 8, 2021
October 7-8: ARK Trades and Storylines
Trading Floor
August 17, 2021
August 16-17, 2021: ARK Trades and Storylines
Trading Floor
July 21, 2021
ARK Quarterly Webinar Summary and Notes
Trading Floor
December 14, 2020
Two-Part post to show the similarities in the charts of Intellia Therapeutics and Pure Storage
Trading Floor
October 12, 2020
#243: After A Nobel Prize, What’s Next for CRISPR Cas9, & More
See Section #1August 24, 2020
#236: Baidu’s Apollo Go Is A Smart Step Toward Launching Fully Autonomous Taxis, & More
See Section #3June 8, 2020